The Bayer AG is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. At the same time Bayer creates value through innovation, growth and improved earning power.
Bayer HealthCare AG researches, develops, manufactures and markets innovative products for disease prevention, diagnosis and treatment. Bayer CropScience AG is a global leader in crop protection and non-agricultural pest control.
Bayer MaterialScience AG is a renowned supplier of high-performance materials and innovative system solutions used in a wide range of products for everyday life.
The Group is committed to the principles of sustainable development and acknowledges and accepts its role as a socially and ethically responsible 'corporate citizen'. Economy, ecology and social responsibility are corporate policy objectives of equal rank.
Bayer HealthCare AG researches, develops, manufactures and markets innovative products for disease prevention, diagnosis and treatment. Bayer CropScience AG is a global leader in crop protection and non-agricultural pest control.
Bayer MaterialScience AG is a renowned supplier of high-performance materials and innovative system solutions used in a wide range of products for everyday life.
The Group is committed to the principles of sustainable development and acknowledges and accepts its role as a socially and ethically responsible 'corporate citizen'. Economy, ecology and social responsibility are corporate policy objectives of equal rank.
The Bayer AG has P/E Ratio34.54, Earnings per Share (gross) in €2.26 Earnings per Share (net) in €1.64, Shares outstanding 826,947,808, Market Capitalization in m. €46,945.83 Freefloat Market Capitalisation in m. €46,945.83 and beta coefficient 0.95.
Bayer HealthCare and Regeneron Pharmaceuticals, Inc. on December 20, 2010 announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO). In this trial, 56.1 percent of patients receiving VEGF Trap-Eye 2 milligrams (mg) monthly gained at least 15 letters of vision from baseline, compared to 12.3 percent of patients receiving sham injections (p<0.0001), the primary endpoint of the study. Patients receiving VEGF Trap-Eye 2mg monthly gained, on average, 17.3 letters of vision compared to a mean loss of 4.0 letters with sham injections (p<0.001), a secondary endpoint. The second Phase 3 study, GALILEO, is currently ongoing and is led by Bayer HealthCare.
“In the COPERNICUS trial, patients treated with VEGF Trap-Eye experienced a marked improvement in vision,” said George D. Yancopoulos, M.D., Ph.D., President of Regeneron Research Laboratories. “If these results are confirmed by data from the GALILEO study, expected in the second quarter of 2011, VEGF Trap-Eye could provide patients and physicians with a new treatment option for central retinal vein occlusion.”
“After reporting positive results from our global Phase 3 program (VIEW 1 and VIEW 2 studies) for the treatment of the neovascular form of age related macular degeneration (wet AMD), we are pleased to also have a positive Phase 3 trial with VEGF Trap-Eye in central retinal vein occlusion, a potential second indication,” said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee. “We are working diligently with Regeneron to prepare regulatory filings for VEGF Trap-Eye in wet AMD to submit in the first half of 2011.”
VEGF Trap-Eye was generally well tolerated and the most common adverse events were those typically associated with intravitreal injections or the underlying disease. A total of 114 patients were randomized to receive VEGF Trap-Eye and 73 patients to the control arm. Serious ocular adverse events in the VEGF Trap-Eye group were uncommon (3.5%) and were more frequent in the control group (13.5%). The incidence of non-ocular serious adverse events was generally well-balanced between the treatment arms. There were no deaths among the 114 patients treated with VEGF Trap-Eye and two in the 73 (2.7%) patients treated with sham injections.
Detailed results for COPERNICUS will be presented at the Angiogenesis Conference in Miami, Florida in February 2011.
“After reporting positive results from our global Phase 3 program (VIEW 1 and VIEW 2 studies) for the treatment of the neovascular form of age related macular degeneration (wet AMD), we are pleased to also have a positive Phase 3 trial with VEGF Trap-Eye in central retinal vein occlusion, a potential second indication,” said Kemal Malik, MD, Head of Global Development and member of the Bayer HealthCare Executive Committee. “We are working diligently with Regeneron to prepare regulatory filings for VEGF Trap-Eye in wet AMD to submit in the first half of 2011.”
VEGF Trap-Eye was generally well tolerated and the most common adverse events were those typically associated with intravitreal injections or the underlying disease. A total of 114 patients were randomized to receive VEGF Trap-Eye and 73 patients to the control arm. Serious ocular adverse events in the VEGF Trap-Eye group were uncommon (3.5%) and were more frequent in the control group (13.5%). The incidence of non-ocular serious adverse events was generally well-balanced between the treatment arms. There were no deaths among the 114 patients treated with VEGF Trap-Eye and two in the 73 (2.7%) patients treated with sham injections.
Detailed results for COPERNICUS will be presented at the Angiogenesis Conference in Miami, Florida in February 2011.
Tidak ada komentar:
Posting Komentar